A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Completed · Phase 2

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.

Key facts

Study ID

NCT00443391

Run by

AbbVie (prior sponsor, Abbott)

People needed

141

Starts

2007-02-01

Expected to finish

2008-10-01

Last updated by the study team

2013-01-18

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject was randomized into Study M06-855 and completed treatment in Periods 1 and 2 and the 2-week Extension Period
• If female, subject must be either postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least a method of birth control throughout the study
• If female, the result of a pregnancy tests are negative
• The subject is judged to be in generally good health

You may not qualify if…

• More than 7 days have elapsed since the last dose of study drug in Study M06-855
• The subject has taken any ADHD medication between the last dose of study drug in Study M06-855 and the first dose of study drug in the current study
• The subject anticipates a move outside the geographic area

Where it is running

• Site Reference ID/Investigator# 6109 — Mesa, Arizona, United States
• Site Reference ID/Investigator# 6765 — Mesa, Arizona, United States
• Site Reference ID/Investigator# 6100 — Lafayette, California, United States
• Site Reference ID/Investigator# 6107 — San Diego, California, United States
• Site Reference ID/Investigator# 6112 — Jacksonville, Florida, United States
• Site Reference ID/Investigator# 6096 — Maitland, Florida, United States
• Site Reference ID/Investigator# 6105 — Tampa, Florida, United States
• Site Reference ID/Investigator# 6094 — Smyrna, Georgia, United States
• Site Reference ID/Investigator# 6111 — Newton, Kansas, United States
• Site Reference ID/Investigator# 6113 — Farmington Hills, Michigan, United States
• Site Reference ID/Investigator# 6110 — Omaha, Nebraska, United States
• Site Reference ID/Investigator# 6099 — New York, New York, United States
• Site Reference ID/Investigator# 6106 — Chapel Hill, North Carolina, United States
• Site Reference ID/Investigator# 6102 — Portland, Oregon, United States
• Site Reference ID/Investigator# 6097 — Charleston, South Carolina, United States
• Site Reference ID/Investigator# 6098 — Memphis, Tennessee, United States
• Site Reference ID/Investigator# 6103 — Austin, Texas, United States
• Site Reference ID/Investigator# 6104 — Lake Jackson, Texas, United States
• Site Reference ID/Investigator# 6095 — Herndon, Virginia, United States
• Site Reference ID/Investigator# 6092 — Seattle, Washington, United States
• Site Reference ID/Investigator# 6101 — Middleton, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.